Fertility, decoded.

Editorial summary.

Pre-conception bloodwork is one of the few moments in U.S. women's healthcare where wide testing is straightforwardly worth the cost. A complete panel — thyroid, prolactin, vitamin D, B12, folate (RBC and serum), HbA1c, and a hormonal subset that depends on age and cycle — ordered three to six months before active trying gives anything addressable time to settle.

The most consequential findings are usually the boring ones. A TSH above 2.5 mIU/L worth bringing down. A low ferritin worth refilling. A B12 in the lower half of range worth investigating. A vitamin D below 30 ng/mL worth replacing. A folate that needs a few months to build up before egg meets sperm. The dramatic stuff — AMH, FSH — gets the attention; the quiet stuff is often the part that meaningfully changes outcomes.

This page walks through what to ask for, why timing matters, and how the various markers fit together — without rushing anyone into a fertility-clinic conversation they may not need.

What's typically going on.

The body's reproductive system runs on a tightly coordinated conversation between brain (hypothalamus and pituitary), ovaries, thyroid, adrenals and a layer of nutritional inputs that most physicals don't measure. When everything is in range, the conversation is automatic and largely invisible. When one of the inputs is running low or the signalling is mistimed, conception can take longer than expected and the early weeks of pregnancy carry higher risk.

Thyroid is the single most consequential modifiable input in pre-conception bloodwork. Major societies — including the American Thyroid Association — recommend a lower TSH target (commonly under 2.5 mIU/L) in women trying to conceive and in early pregnancy. The reason is not abstract: higher TSH in early pregnancy is associated with increased miscarriage risk, and thyroid antibodies positivity adds to that risk even at TSH levels that would otherwise look fine. This is one of the few "boring" labs that meaningfully changes outcomes.

The hormonal subset — AMH, FSH, estradiol, LH, progesterone — answers a different question. AMH reflects ovarian reserve, the number of follicles still in the pool. FSH and estradiol on day 3 of the cycle give a snapshot of how hard the brain is having to push the ovaries that month. Mid-luteal progesterone (roughly day 21 of a 28-day cycle, or seven days after ovulation) confirms whether a given cycle ovulated. These markers are useful, but they are most useful as a panel with context — not single numbers used to predict success or failure.

The nutritional layer — B12, folate (RBC and serum), iron stores, vitamin D — sits underneath all of it. Folate's role is the most well-known, and the most well-evidenced: starting at least one to three months before conception, at 400–800 mcg per day, meaningfully reduces neural tube defect risk and supports broader DNA synthesis through the first trimester. B12 cooperates with folate; HbA1c reflects the average blood sugar environment the embryo will start in. Each is measurable, each is addressable, and each tends to take weeks to months to shift — which is why testing earlier rather than later matters.

"The fertility conversation skips straight to AMH while ignoring the labs that actually change outcomes. Thyroid, folate, B12 and ferritin do the quiet work."

The biomarkers worth knowing.

A reasonable pre-conception panel breaks into three layers: a hormonal subset (cycle-timed), a thyroid-and-pituitary subset, and a nutritional subset. Read together by a qualified healthcare provider, the following catches most of what is modifiable before conception.

None of these markers is useful in isolation. Read together, on a timeline that allows months for anything addressable to settle, they answer a more useful question than a single AMH number ever can.

Common patterns.

4.1 The thyroid pattern

A woman in her early 30s, getting ready to try, comes back with a TSH of 3.4 mIU/L and positive TPO antibodies. Symptoms are unremarkable. The standard primary-care visit calls this "in range." For pre-conception, both numbers matter, and both warrant a conversation with a qualified clinician about whether to treat now rather than wait. This is the highest-yield "boring" finding in pre-conception panels.

4.2 The PCOS pattern

A woman with irregular cycles, acne, possibly weight gain. AMH may be elevated (counter-intuitively — PCOS often presents with high AMH and many follicles), fasting insulin is elevated, mid-luteal progesterone confirms not all cycles ovulate. The right read here is PCOS-aware care from the start — not a year of waiting under the standard "12 months trying" rule.

4.3 The depleted-nutrition pattern

A woman in her late 20s with a B12 in the lower half of range, ferritin under 30 ng/mL, and a vitamin D below 25 ng/mL. Cycles are otherwise regular. The hormonal subset looks fine. The treatable layer is the nutritional one, and addressing it months ahead matters more than the AMH conversation.

4.4 The "diminished reserve" worry pattern

A woman in her late 30s comes back with an AMH below the cohort average for her age. She is told her fertility is "low." This is one of the most consistently misinterpreted lab readings in U.S. women's healthcare. AMH predicts response to fertility medications and gives context; it does not predict natural per-cycle conception success in well-functioning ovulatory cycles. A low AMH is worth knowing, not worth panicking over.

What to ask your provider.

If your current provider declines the wider workup, a second opinion is reasonable. A women's-health nurse practitioner, OB-GYN with fertility experience, or a midwife-led practice that runs pre-conception panels routinely is the right next step.

When to escalate vs when to track over time.

Most pre-conception bloodwork is worth a planned conversation with a qualified clinician — not an urgent fertility-clinic referral. A few exceptions warrant a faster timeline.

Worth a planned conversation. Pre-conception panel several months before active trying. If any results need addressing — TSH, folate, B12, ferritin — re-test six to twelve weeks after intervention before conception. Standard guidance is 12 months of trying under 35, 6 months over 35, before specialist evaluation.

Worth sooner. Known irregular cycles, history of pelvic surgery or infection, known endocrine conditions (PCOS, thyroid disease, diabetes), previous miscarriage(s), family history of early menopause, or age 38+ — all reasonable grounds for earlier evaluation. Symptoms of overt thyroid, prolactin or androgen excess warrant earlier workup regardless of conception timeline.

Worth tracking, not panicking. A borderline AMH or a single elevated FSH in someone with otherwise regular cycles is not a verdict. Trending markers six months apart, in the same lab and cycle window, gives a more honest picture than a single snapshot.